Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 59 | 2024 | 11083 | 5.160 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2024 | 3251 | 1.000 |
Why?
|
Tissue Array Analysis | 3 | 2021 | 545 | 0.950 |
Why?
|
Prostate | 8 | 2023 | 1755 | 0.920 |
Why?
|
Serine Endopeptidases | 5 | 2023 | 1024 | 0.880 |
Why?
|
Organic Anion Transporters | 1 | 2024 | 101 | 0.850 |
Why?
|
PTEN Phosphohydrolase | 4 | 2024 | 1119 | 0.730 |
Why?
|
Neoplasms, Bone Tissue | 1 | 2020 | 7 | 0.710 |
Why?
|
Cholesterol | 4 | 2022 | 2898 | 0.680 |
Why?
|
Squalene Monooxygenase | 2 | 2017 | 11 | 0.680 |
Why?
|
Oncogene Proteins, Fusion | 6 | 2024 | 1608 | 0.660 |
Why?
|
Serine Proteinase Inhibitors | 1 | 2020 | 173 | 0.620 |
Why?
|
Radiation, Ionizing | 1 | 2019 | 249 | 0.600 |
Why?
|
Aspirin | 3 | 2018 | 3134 | 0.590 |
Why?
|
DNA Repair | 4 | 2023 | 2048 | 0.570 |
Why?
|
Sterol O-Acyltransferase | 1 | 2017 | 28 | 0.570 |
Why?
|
NADH, NADPH Oxidoreductases | 1 | 2017 | 96 | 0.560 |
Why?
|
Follow-Up Studies | 25 | 2024 | 39193 | 0.530 |
Why?
|
Male | 73 | 2024 | 363698 | 0.520 |
Why?
|
Gangrene | 1 | 2016 | 92 | 0.500 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2024 | 2878 | 0.490 |
Why?
|
Nonprescription Drugs | 1 | 2016 | 119 | 0.490 |
Why?
|
BRCA1 Protein | 2 | 2023 | 1153 | 0.470 |
Why?
|
Receptors, LDL | 1 | 2017 | 491 | 0.470 |
Why?
|
Genes, Tumor Suppressor | 1 | 2019 | 1061 | 0.460 |
Why?
|
Oncogenes | 1 | 2020 | 1235 | 0.450 |
Why?
|
Vitamin D | 2 | 2024 | 3272 | 0.420 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1084 | 0.410 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2023 | 2942 | 0.390 |
Why?
|
Foot | 1 | 2016 | 573 | 0.380 |
Why?
|
Gene Expression Regulation, Neoplastic | 8 | 2024 | 8611 | 0.380 |
Why?
|
Signal Transduction | 4 | 2024 | 23601 | 0.380 |
Why?
|
Metformin | 2 | 2016 | 904 | 0.370 |
Why?
|
Prospective Studies | 16 | 2024 | 54802 | 0.360 |
Why?
|
Humans | 81 | 2024 | 765968 | 0.360 |
Why?
|
Radiation Dosage | 1 | 2019 | 1944 | 0.350 |
Why?
|
Genetic Variation | 3 | 2020 | 6610 | 0.320 |
Why?
|
Prescription Drugs | 1 | 2016 | 634 | 0.320 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 2268 | 0.300 |
Why?
|
Aneuploidy | 2 | 2024 | 578 | 0.300 |
Why?
|
Phthalazines | 2 | 2020 | 397 | 0.290 |
Why?
|
Aged | 25 | 2024 | 171117 | 0.260 |
Why?
|
Age Factors | 1 | 2022 | 18380 | 0.250 |
Why?
|
Prognosis | 10 | 2023 | 29922 | 0.250 |
Why?
|
Dietary Supplements | 2 | 2024 | 3425 | 0.240 |
Why?
|
Prostate-Specific Antigen | 4 | 2022 | 2464 | 0.230 |
Why?
|
Chromosome Painting | 1 | 2024 | 26 | 0.230 |
Why?
|
Genomics | 1 | 2020 | 5929 | 0.220 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 10383 | 0.220 |
Why?
|
Trypsin Inhibitor, Kazal Pancreatic | 1 | 2023 | 30 | 0.220 |
Why?
|
Middle Aged | 24 | 2024 | 223009 | 0.220 |
Why?
|
Neoplasm Metastasis | 3 | 2024 | 4893 | 0.210 |
Why?
|
Chromosomes, Human, Y | 1 | 2024 | 163 | 0.210 |
Why?
|
Phenotype | 2 | 2020 | 16721 | 0.200 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3100 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3223 | 0.200 |
Why?
|
Receptors, Calcitriol | 1 | 2024 | 361 | 0.200 |
Why?
|
Prostatitis | 1 | 2022 | 102 | 0.190 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2023 | 312 | 0.190 |
Why?
|
BRCA2 Protein | 3 | 2022 | 800 | 0.190 |
Why?
|
Antineoplastic Agents | 3 | 2020 | 13648 | 0.190 |
Why?
|
Diabetes Mellitus | 2 | 2020 | 5891 | 0.190 |
Why?
|
RNA Editing | 1 | 2022 | 148 | 0.180 |
Why?
|
5-alpha Reductase Inhibitors | 1 | 2022 | 114 | 0.180 |
Why?
|
Microsatellite Instability | 1 | 2024 | 728 | 0.180 |
Why?
|
Gabexate | 1 | 2020 | 12 | 0.180 |
Why?
|
Stathmin | 1 | 2020 | 68 | 0.170 |
Why?
|
Androgen Antagonists | 3 | 2024 | 1411 | 0.170 |
Why?
|
Disease Progression | 3 | 2024 | 13632 | 0.170 |
Why?
|
Piperazines | 2 | 2020 | 2549 | 0.170 |
Why?
|
p300-CBP Transcription Factors | 1 | 2021 | 147 | 0.170 |
Why?
|
Coffee | 1 | 2024 | 593 | 0.170 |
Why?
|
Arm | 1 | 2022 | 589 | 0.160 |
Why?
|
Paraffin Embedding | 1 | 2020 | 301 | 0.160 |
Why?
|
Androgens | 2 | 2024 | 1279 | 0.160 |
Why?
|
Epidemiologic Studies | 1 | 2023 | 677 | 0.160 |
Why?
|
Guanidines | 1 | 2020 | 194 | 0.160 |
Why?
|
Esters | 1 | 2020 | 214 | 0.160 |
Why?
|
Cyclic AMP Response Element-Binding Protein | 1 | 2021 | 499 | 0.150 |
Why?
|
src-Family Kinases | 1 | 2020 | 538 | 0.150 |
Why?
|
Genetic Predisposition to Disease | 4 | 2024 | 18071 | 0.150 |
Why?
|
Neoplasm Staging | 4 | 2021 | 11206 | 0.150 |
Why?
|
Orchiectomy | 1 | 2020 | 460 | 0.150 |
Why?
|
Adult | 18 | 2024 | 223044 | 0.140 |
Why?
|
Dyslexia, Acquired | 1 | 2017 | 14 | 0.140 |
Why?
|
Environment | 1 | 2023 | 1114 | 0.140 |
Why?
|
Risk Factors | 10 | 2024 | 74840 | 0.140 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2020 | 660 | 0.130 |
Why?
|
Trypsinogen | 1 | 2016 | 84 | 0.130 |
Why?
|
Cryoglobulins | 1 | 2016 | 58 | 0.130 |
Why?
|
Reproducibility of Results | 3 | 2024 | 20124 | 0.130 |
Why?
|
Fluorescent Antibody Technique | 1 | 2020 | 2476 | 0.130 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 20659 | 0.130 |
Why?
|
Cell Cycle Proteins | 2 | 2024 | 3430 | 0.130 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2022 | 950 | 0.120 |
Why?
|
Vitamins | 1 | 2024 | 1630 | 0.120 |
Why?
|
Cryoglobulinemia | 1 | 2016 | 83 | 0.120 |
Why?
|
Incidence | 4 | 2023 | 21480 | 0.120 |
Why?
|
Candidiasis | 1 | 2018 | 371 | 0.120 |
Why?
|
Plasmapheresis | 1 | 2016 | 205 | 0.120 |
Why?
|
Gene Expression Profiling | 2 | 2023 | 9525 | 0.120 |
Why?
|
DNA Copy Number Variations | 2 | 2022 | 2045 | 0.120 |
Why?
|
Histocompatibility | 1 | 2016 | 327 | 0.120 |
Why?
|
Toes | 1 | 2016 | 209 | 0.120 |
Why?
|
Cohort Studies | 6 | 2024 | 41649 | 0.120 |
Why?
|
Mutation | 6 | 2024 | 30198 | 0.110 |
Why?
|
Cost of Illness | 1 | 2023 | 1950 | 0.110 |
Why?
|
Epigenomics | 1 | 2018 | 959 | 0.100 |
Why?
|
Neoplasms, Second Primary | 1 | 2020 | 1050 | 0.100 |
Why?
|
Population Surveillance | 1 | 2023 | 2590 | 0.100 |
Why?
|
Chromosome Aberrations | 1 | 2019 | 1774 | 0.100 |
Why?
|
Hematologic Neoplasms | 1 | 2024 | 1927 | 0.100 |
Why?
|
Biopsy | 1 | 2023 | 6763 | 0.100 |
Why?
|
Uropathogenic Escherichia coli | 1 | 2011 | 6 | 0.090 |
Why?
|
Health Status Disparities | 1 | 2023 | 1880 | 0.090 |
Why?
|
Neonatal Screening | 1 | 2016 | 627 | 0.090 |
Why?
|
Software | 2 | 2024 | 4462 | 0.090 |
Why?
|
Immunohistochemistry | 2 | 2021 | 11022 | 0.090 |
Why?
|
Aged, 80 and over | 6 | 2024 | 59489 | 0.090 |
Why?
|
DNA-Binding Proteins | 2 | 2024 | 9601 | 0.090 |
Why?
|
Blastocystis Infections | 1 | 2010 | 17 | 0.090 |
Why?
|
Blastocystis | 1 | 2010 | 21 | 0.080 |
Why?
|
Self Report | 1 | 2021 | 3770 | 0.080 |
Why?
|
Intestinal Diseases, Parasitic | 1 | 2010 | 64 | 0.080 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 1514 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 1 | 2020 | 6499 | 0.080 |
Why?
|
United States | 6 | 2024 | 72903 | 0.080 |
Why?
|
Genotype | 1 | 2024 | 13024 | 0.080 |
Why?
|
Genetic Association Studies | 1 | 2018 | 2741 | 0.080 |
Why?
|
Single-Cell Analysis | 1 | 2020 | 2535 | 0.080 |
Why?
|
Influenza, Human | 1 | 2020 | 1539 | 0.080 |
Why?
|
Urticaria | 1 | 2010 | 151 | 0.080 |
Why?
|
Delivery of Health Care | 2 | 2023 | 5370 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2021 | 5337 | 0.070 |
Why?
|
Neoplasm Proteins | 1 | 2020 | 3596 | 0.070 |
Why?
|
Proportional Hazards Models | 4 | 2024 | 12509 | 0.070 |
Why?
|
Healthcare Disparities | 1 | 2023 | 3413 | 0.070 |
Why?
|
Escherichia coli Infections | 1 | 2011 | 519 | 0.070 |
Why?
|
Cystic Fibrosis | 1 | 2016 | 1287 | 0.070 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2022 | 16047 | 0.060 |
Why?
|
Exercise | 2 | 2023 | 5937 | 0.060 |
Why?
|
Cell Line, Tumor | 2 | 2021 | 17075 | 0.060 |
Why?
|
Neoplasms | 3 | 2024 | 22340 | 0.060 |
Why?
|
Survival Rate | 4 | 2020 | 12795 | 0.060 |
Why?
|
Breast Neoplasms | 2 | 2022 | 21056 | 0.060 |
Why?
|
Urinary Tract Infections | 1 | 2011 | 805 | 0.060 |
Why?
|
Electronic Health Records | 1 | 2022 | 4873 | 0.060 |
Why?
|
Hematopoiesis | 2 | 2024 | 2058 | 0.060 |
Why?
|
Genome-Wide Association Study | 1 | 2023 | 12807 | 0.060 |
Why?
|
Survival Analysis | 1 | 2016 | 10070 | 0.050 |
Why?
|
Risk | 1 | 2015 | 9591 | 0.050 |
Why?
|
Residence Characteristics | 2 | 2023 | 2116 | 0.050 |
Why?
|
Retrospective Studies | 4 | 2022 | 81514 | 0.050 |
Why?
|
Genome | 2 | 2022 | 1753 | 0.050 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 2024 | 451 | 0.050 |
Why?
|
Marital Status | 1 | 2024 | 426 | 0.050 |
Why?
|
Gene Expression Regulation | 1 | 2020 | 11888 | 0.050 |
Why?
|
Class Ia Phosphatidylinositol 3-Kinase | 1 | 2022 | 76 | 0.050 |
Why?
|
Life Style | 2 | 2024 | 3926 | 0.050 |
Why?
|
Spain | 1 | 2022 | 483 | 0.050 |
Why?
|
DNA Mismatch Repair | 1 | 2024 | 433 | 0.050 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2022 | 303 | 0.050 |
Why?
|
Young Adult | 5 | 2020 | 59889 | 0.050 |
Why?
|
Sweden | 1 | 2024 | 1381 | 0.050 |
Why?
|
Adenocarcinoma | 1 | 2018 | 6364 | 0.050 |
Why?
|
Pandemics | 1 | 2020 | 8703 | 0.040 |
Why?
|
Algorithms | 1 | 2020 | 14071 | 0.040 |
Why?
|
Histone Demethylases | 1 | 2022 | 328 | 0.040 |
Why?
|
Germ Cells | 1 | 2023 | 647 | 0.040 |
Why?
|
Chromosomes | 1 | 2022 | 578 | 0.040 |
Why?
|
Genetic Fitness | 1 | 2020 | 119 | 0.040 |
Why?
|
Tumor Microenvironment | 2 | 2023 | 3946 | 0.040 |
Why?
|
Chromosome Deletion | 1 | 2024 | 1385 | 0.040 |
Why?
|
Taxoids | 1 | 2022 | 665 | 0.040 |
Why?
|
Female | 9 | 2022 | 396112 | 0.040 |
Why?
|
Zinc | 1 | 2022 | 675 | 0.040 |
Why?
|
Glycolysis | 1 | 2022 | 838 | 0.040 |
Why?
|
Genomic Instability | 1 | 2022 | 718 | 0.040 |
Why?
|
Lysine | 1 | 2022 | 991 | 0.040 |
Why?
|
Organoids | 1 | 2024 | 739 | 0.040 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2016 | 5753 | 0.040 |
Why?
|
Genetics, Population | 1 | 2022 | 943 | 0.040 |
Why?
|
Leukemia, Myeloid | 1 | 2020 | 696 | 0.040 |
Why?
|
beta-Glucans | 1 | 2018 | 129 | 0.030 |
Why?
|
Europe | 1 | 2024 | 3423 | 0.030 |
Why?
|
Registries | 2 | 2024 | 8297 | 0.030 |
Why?
|
Diet, Mediterranean | 1 | 2024 | 746 | 0.030 |
Why?
|
Drug Synergism | 1 | 2020 | 1749 | 0.030 |
Why?
|
Genes, BRCA2 | 1 | 2019 | 588 | 0.030 |
Why?
|
Chemistry Techniques, Analytical | 1 | 2016 | 48 | 0.030 |
Why?
|
Receptors, Androgen | 1 | 2022 | 1088 | 0.030 |
Why?
|
Selection, Genetic | 1 | 2020 | 878 | 0.030 |
Why?
|
Treatment Outcome | 2 | 2020 | 65188 | 0.030 |
Why?
|
Hemianopsia | 1 | 2017 | 121 | 0.030 |
Why?
|
Actins | 1 | 2022 | 2056 | 0.030 |
Why?
|
Candida albicans | 1 | 2018 | 377 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2023 | 1884 | 0.030 |
Why?
|
Writing | 1 | 2017 | 199 | 0.030 |
Why?
|
Prostatectomy | 1 | 2022 | 1782 | 0.030 |
Why?
|
DNA Damage | 1 | 2024 | 2457 | 0.030 |
Why?
|
Social Class | 1 | 2023 | 2007 | 0.030 |
Why?
|
Adolescent | 2 | 2020 | 88835 | 0.030 |
Why?
|
Mice, Nude | 1 | 2020 | 3618 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2022 | 2034 | 0.030 |
Why?
|
Social Support | 1 | 2024 | 2192 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2022 | 2453 | 0.030 |
Why?
|
Reading | 1 | 2017 | 539 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2020 | 6113 | 0.030 |
Why?
|
Trans-Activators | 1 | 2022 | 2850 | 0.030 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2020 | 3608 | 0.020 |
Why?
|
Medical Oncology | 1 | 2024 | 2339 | 0.020 |
Why?
|
RNA | 1 | 2022 | 2717 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2024 | 3655 | 0.020 |
Why?
|
Cell Adhesion | 1 | 2018 | 3089 | 0.020 |
Why?
|
Pattern Recognition, Visual | 1 | 2017 | 820 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2020 | 2844 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2020 | 6309 | 0.020 |
Why?
|
HLA Antigens | 1 | 2016 | 1339 | 0.020 |
Why?
|
Paromomycin | 1 | 2010 | 14 | 0.020 |
Why?
|
Hematopoietic Stem Cells | 1 | 2023 | 3401 | 0.020 |
Why?
|
Phosphorylation | 1 | 2021 | 8278 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2024 | 5783 | 0.020 |
Why?
|
Risk Assessment | 2 | 2022 | 24282 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2023 | 7838 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2022 | 4913 | 0.020 |
Why?
|
Metronidazole | 1 | 2010 | 236 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2020 | 26346 | 0.020 |
Why?
|
Insulin | 1 | 2022 | 6599 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2022 | 3236 | 0.020 |
Why?
|
Virulence Factors | 1 | 2011 | 500 | 0.020 |
Why?
|
Logistic Models | 1 | 2020 | 13266 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2020 | 10429 | 0.010 |
Why?
|
Apoptosis | 1 | 2020 | 9514 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15398 | 0.010 |
Why?
|
Infant | 2 | 2020 | 36386 | 0.010 |
Why?
|
Models, Biological | 1 | 2020 | 9443 | 0.010 |
Why?
|
Escherichia coli Proteins | 1 | 2011 | 1057 | 0.010 |
Why?
|
Cell Line | 1 | 2018 | 15543 | 0.010 |
Why?
|
Gastrointestinal Tract | 1 | 2010 | 834 | 0.010 |
Why?
|
Child, Preschool | 2 | 2020 | 42500 | 0.010 |
Why?
|
Drug Resistance, Bacterial | 1 | 2011 | 1069 | 0.010 |
Why?
|
Inflammation | 1 | 2023 | 10850 | 0.010 |
Why?
|
Graft vs Host Disease | 1 | 2016 | 3078 | 0.010 |
Why?
|
Mice | 2 | 2020 | 81819 | 0.010 |
Why?
|
Anti-Infective Agents | 1 | 2010 | 986 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 14652 | 0.010 |
Why?
|
Animals | 3 | 2020 | 168764 | 0.010 |
Why?
|
Child | 2 | 2020 | 80564 | 0.010 |
Why?
|
Recurrence | 1 | 2010 | 8501 | 0.010 |
Why?
|
Chronic Disease | 1 | 2010 | 9347 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2011 | 7478 | 0.010 |
Why?
|
Brain | 1 | 2017 | 27171 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2017 | 36532 | 0.010 |
Why?
|